Bolt Biotherapeutics

BOLT · NASDAQ

$4.31+$0.27 (+6.68%)TodayMarket closed · Oct 20, 4:10 PM ET

Prev close $4.04

Latest news

NewsAug 12, 1:05 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
Press releaseAug 11, 4:05 PM ETGlobe Newswire
Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Press releaseMay 12, 4:05 PM ETGlobe Newswire
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Press releaseMar 12, 4:05 PM ETGlobe Newswire
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
Press releaseNov 12, 4:05 PM ETGlobe Newswire
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
NewsOct 2, 8:09 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Press releaseOct 1, 4:05 PM ETGlobe Newswire
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
NewsAug 27, 8:08 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Press releaseAug 14, 4:05 PM ETGlobe Newswire
Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
NewsAug 1, 8:07 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
Press releaseMay 12, 4:05 PM ETGlobe Newswire
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Press releaseApr 30, 4:05 PM ETGlobe Newswire
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025
Press releaseApr 25, 1:00 PM ETGlobe Newswire
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
Press releaseMar 24, 4:20 PM ETGlobe Newswire
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
Press releaseSep 3, 3:19 PM ETPRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT
Press releaseSep 3, 10:20 AM ETBusiness Wire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Press releaseSep 3, 12:00 AM ETPRNewswire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Press releaseSep 2, 11:11 AM ETBusiness Wire
BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Press releaseAug 31, 11:25 AM ETPRNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt
Press releaseAug 30, 9:00 PM ETGlobe Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, SeaStar, and Bolt and Encourages Investors to Contact the Firm
Press releaseAug 30, 4:14 PM ETPRNewswire
BOLT Deadline: BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit
Press releaseAug 29, 8:49 PM ETGlobe Newswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt
Press releaseAug 27, 4:47 PM ETPRNewswire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Press releaseAug 26, 9:00 PM ETGlobe Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, SeaStar, and Bolt and Encourages Investors to Contact the Firm
Press releaseAug 26, 3:50 PM ETPRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT
Press releaseAug 26, 11:05 AM ETPRNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt
Press releaseAug 23, 7:30 PM ETPRNewswire
BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit
Press releaseAug 22, 9:00 AM ETPRNewswire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Press releaseAug 21, 11:47 AM ETPRNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt
Press releaseAug 20, 9:00 PM ETGlobe Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, FutureFuel, SeaStar, and Bolt and Encourages Investors to Contact the Firm
Press releaseAug 17, 10:00 AM ETPRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT
Press releaseAug 16, 9:00 PM ETGlobe Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NIKE, FutureFuel, SeaStar, and Bolt and Encourages Investors to Contact the Firm
Press releaseAug 16, 8:00 PM ETPRNewswire
BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit
Press releaseAug 14, 1:59 PM ETPRNewswire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Press releaseAug 14, 11:15 AM ETPRNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt
Press releaseAug 12, 9:00 PM ETGlobe Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NIKE, FutureFuel, SeaStar, and Bolt and Encourages Investors to Contact the Firm
Press releaseAug 9, 10:00 AM ETPRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT
Press releaseAug 8, 5:45 PM ETPRNewswire
BOLT Investors Have Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit
Press releaseAug 7, 11:05 AM ETPRNewswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt
Press releaseAug 6, 9:00 PM ETGlobe Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, SeaStar, and Bolt and Encourages Investors to Contact the Firm

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

12 Health Care Stocks Moving In Wednesday's Intraday Session

Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

12 Health Care Stocks Moving In Friday's Pre-Market Session

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT

BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, SeaStar, and Bolt and Encourages Investors to Contact the Firm

BOLT Deadline: BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, SeaStar, and Bolt and Encourages Investors to Contact the Firm

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit

BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, FutureFuel, SeaStar, and Bolt and Encourages Investors to Contact the Firm

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NIKE, FutureFuel, SeaStar, and Bolt and Encourages Investors to Contact the Firm

BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit

BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NIKE, FutureFuel, SeaStar, and Bolt and Encourages Investors to Contact the Firm

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT

BOLT Investors Have Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, SeaStar, and Bolt and Encourages Investors to Contact the Firm